RNA Therapeutics (eBook, ePUB)

The Evolving Landscape of RNA Therapeutics
Redaktion: Giangrande, Paloma H.; Rossi, John J.; de Franciscis, Vittorio

• Format: ePub

Produktbeschreibung

RNA Therapeutics: The Evolving Landscape of RNA Therapeutics provides a comprehensive overview of RNA therapeutic modalities, from bench-to-bedside, with an emphasis on the increasingly impactful areas of gene therapy, oligonucleotide therapeutics, gene editing and delivery. International leaders in the field examine RNA-based therapeutics tools that have been developed to-date to modulate cellular processes such as transcription, translation and protein function. Approved RNA-based therapies and lessons learned from failed therapies are discussed in-depth, as are evolving advances in RNA biochemical analysis, and similar advances that are enabling clinical application of RNA-based therapies.

Later sections discuss delivery technologies, remaining hurdles in research and translation, the therapy development process from the lab to the clinic, and novel RNA-based therapies currently in development.

• Features leading experts in the field of RNA therapeutics, spanning all classes of RNA therapies
• Provides a detailed examination of approved RNA therapies and lessons learned from failed therapeutics
• Covers all aspects of therapeutic discovery and preclinical development, as well as clinical translation, manufacturing and regulatory aspects

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 472
• Erscheinungstermin: 10. April 2022
• Englisch
• ISBN-13: 9780128217399
• Artikelnr.: 63739559

Inhaltsangabe

SECTION 1 The world of RNA therapeutics: Available RNA tools to modulate
cellular processes
1. Targeting chromatin: Transcriptional gene activation (saRNA)
2. Argonaute and TNRC6, partners in RNAi
3. Targeted RNA therapeutics for treatment of cancer and immunomodulation
4. Extrahepatic delivery of RNA to immune cells
SECTION 2 Learning from history
5. Aptamer-based protein inhibitors
6. Lessons learned from developing an oligonucleotide drug for a rare
disease
SECTION 3 Delivery
7. Nucleoside modifications of in vitro transcribed mRNA to reduce
immunogenicity and improve translation of prophylactic and therapeutic
antigens
8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers
and their applications in therapeutics, diagnostics, and proteomics
SECTION 4 From bench to bedside
9. CMC and regulatory aspects of oligonucleotide therapeutics
10. CMC: Regulatory landscape
11. CMC and manufacturing
SECTION 5 From bench to bedside
12. RNA delivery for cancer gene therapy
13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and
directions